Cytotoxic effects of treosulfan on prostate cancer cell lines. 2007

Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
Department of Urology, University of Tübingen Medical Center, Tübingen, Germany.

OBJECTIVE Despite various therapeutical options in metastatic prostate cancer, the lack of a curative approach motivates further investigations. Treosulfan is an alkylating agent that has proven its indication in the treatment of e.g. ovarian carcinoma. This study focused on the objective of evaluating the effect of in vitro intoxication of human prostate carcinoma cell lines with treosulfan. METHODS Human prostate cancer cell lines LNCaP, DU145 and PC3 were treated with treosulfan concentrations from 0.5-500 microM for up to six days. Analysis of cell viability was performed using colorimetric WST-1 assay. Control data were obtained from identical cell lines cultivated without treosulfan. RESULTS Incubation with treosulfan inhibited cell viability and led to cell death in all cell lines in a dose- and time-dependent manner. After one day, viability of LNCaP, DU145 and PC3 cells was constantly reduced with a dose rate of at least 10 microM (p < 0.001), 10 microM (p < 0.0001) and 100 microM (p < 0.0001) treosulfan, respectively. Minimum dose rates leading to death of nearly all LNCaP, DU145 and PC3 cells were 250 microM, 100 microM and 200 microM treosulfan, respectively. CONCLUSIONS The results demonstrate a sensitivity of prostate carcinoma cells to the cytotoxic activity of treosulfan. Therefore, treosulfan might be a promising compound for novel treatment protocols for prostate cancer.

UI MeSH Term Description Entries
D008297 Male Males
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D048708 Cell Growth Processes Processes required for CELL ENLARGEMENT and CELL PROLIFERATION. Processes, Cell Growth
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating

Related Publications

Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
April 2014, Anticancer research,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
March 2012, Journal of biosciences,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
January 2011, International journal of clinical pharmacology and therapeutics,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
October 1998, Archiv der Pharmazie,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
September 2023, Microbial cell factories,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
January 2022, Current drug discovery technologies,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
August 2008, Investigational new drugs,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
July 2008, Journal of ethnopharmacology,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
March 2007, Journal of ethnopharmacology,
Susan Feyerabend, and Gerhard Feil, and Jutta Krug, and Annette Kassen, and Arnulf Stenzl
February 2005, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!